Anti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacy.

This study focuses on anti-d monoclonal antibodies from 23 human and rodent cell lines display diverse igg fc-glycosylation profiles that determine their clinical efficacy.. The research employs high-performance liquid chromatography (HPLC) techniques to address analytical challenges in the biopharmaceutical field. Anti-D immunoglobulin (Anti-D Ig) prophylaxis prevents haemolytic disease of the fetus and newborn. Monoclonal IgG anti-Ds (mAb-Ds) would enable unlimited supplies but have differed in efficacy in FcγRIIIa-mediated ADCC assays and clinical trials. Structural variations of the oligosaccharide chains of mAb-Ds are hypothesised to be responsible. Quantitative data on 12... Research Background and Significance The study focuses on the characterization of anti-D monoclonal antibodies (mAb-Ds) derived from 23 different human and rodent cell lines, emphasizing the diverse IgG Fc-glycosylation profiles that critically influence their clinical efficacy. Anti-D immunoglobulin therapy is a cornerstone in preventing haemolytic disease of the fetus and newborn (HDFN) by targeting RhD-positive fetal red blood cells in RhD-negative mothers. Despite the clinical success of plasma-derived polyclonal anti-D, supply limitations and batch inconsistencies have driven efforts to develop monoclonal anti-D antibodies. However, variable clinical outcomes and inconsistent antibody-dependent cellular cytotoxicity (ADCC) efficacy have hindered their widespread adoption. Glycosylation of the Fc region of IgG antibodies, especially oligosaccharide chain structures, plays a crucial role in modulating Fc receptor binding and ADCC activity. This study is significant because it systematically evaluates the glycosylation heterogeneity across multiple cell lines, aiming to correlate these struc